SCM
CLRB icon

Sterneck Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Sterneck Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$21K – 95
2022
Q1 		$21K Hold
100
– – 0.01% 101
2021
Q4 		$20K Hold
100
– – 0.01% 104
2021
Q3 		$28K Hold
100
– – 0.02% 99
2021
Q2 		$34K Buy
+100
New +$43.4K 0.02% 98

Other funds holding CLRB

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sterneck Capital Management's CLRB Position: Q2 2022 in Review

Sterneck Capital Management sold out of Cellectar Biosciences (CLRB) in Q2 2022, closing a stake of 100 shares — an estimated $21K sold.

Sterneck Capital Management first reported a position in CLRB in Q2 2021 and held it in 4 quarters. The position peaked at $34K in Q2 2021. 31 funds tracked by Wall St. Rank hold CLRB as of Q2 2022.

  • Sterneck Capital Management reported no remaining Cellectar Biosciences position as of Q2 2022 after selling out during the quarter.
  • Sterneck Capital Management sold 100 Cellectar Biosciences shares in Q2 2022, an estimated $21K.
  • Sterneck Capital Management first reported a position in Cellectar Biosciences in Q2 2021 and held it in 4 quarters.
  • Sterneck Capital Management's Cellectar Biosciences position peaked at $34K in Q2 2021.
  • 31 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2022.

Based on Sterneck Capital Management's 13F filing for Q2 2022, filed 10 Aug 2022.